GSK wagers up to $1.3B on a different kind of cancer drug
BioPharma Dive
With its latest foray into China, GSK acquired rights from Hutchmed to an antibody-targeted therapy conjugate impacting two well-known cancer drivers, EGFR and KRAS.
pharminent
September 3, 2026 (Last updated: September 7, 2026)
BioPharma Dive
With its latest foray into China, GSK acquired rights from Hutchmed to an antibody-targeted therapy conjugate impacting two well-known cancer drivers, EGFR and KRAS.